Having trouble accessing articles? Reset your cache.

Lintuzumab: Development discontinued

Seattle Genetics discontinued development of lintuzumab after data from a double-blind, international Phase IIb trial in 211 previously untreated AML patients >=60

Read the full 226 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE